Case ReportsTreatment of Catatonia With AmantadineHervey, William M. MD*; Stewart, Jonathan T. MD*†; Catalano, Glenn MD,*†Author Information *University of South Florida College of Medicine, Tampa, FL; †Mental Health and Behavioral Sciences Service, James A Haley VA Hospital, University of South Florida College of Medicine, Tampa, FL. Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare. There was no funding for this work. Address correspondence and reprint requests to Jonathan T. Stewart, MD, Mental Health and Behavioral Sciences Service (116A), James A Haley VA Hospital, 13000 Bruce B Downs Blvd, Tampa, FL 33612; E-mail: firstname.lastname@example.org Clinical Neuropharmacology: March/April 2012 - Volume 35 - Issue 2 - p 86-87 doi: 10.1097/WNF.0b013e318246ad34 Buy Metrics Abstract Catatonia is an episodic syndrome characterized by specific affective, behavioral, and motor symptoms and thought to result from regional abnormalities in neurotransmitter function. Although generally thought to represent a manifestation of schizophrenia or depression, there is strong evidence that it may represent a distinct entity, caused by a number of psychogenic, infectious, iatrogenic, and neurological conditions. The morbidity associated with catatonia is significant, and, in some cases, the condition may be life threatening. © 2012 Lippincott Williams & Wilkins, Inc.